Page last updated: 2024-08-22

Brilliant Blue and Wallerian Degeneration

Brilliant Blue has been researched along with Wallerian Degeneration in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bittner, GD; Boyer, RB; Cardwell, NL; Driscoll, CW; McGill, CH; Mikesh, MA; Nanney, LB; Pollins, AC; Rodriguez-Feo, CL; Sexton, KW; Shack, RB; Thayer, WP	1

Other Studies

1 other study(ies) available for Brilliant Blue and Wallerian Degeneration

Article	Year
Blocking the P2X7 receptor improves outcomes after axonal fusion. The Journal of surgical research, 2013, Volume: 184, Issue:1 Topics: Action Potentials; Adenosine Triphosphate; Animals; Axons; Benzenesulfonates; Coloring Agents; Drug Carriers; Male; Motor Activity; Nerve Regeneration; Neurosurgical Procedures; Platelet Aggregation Inhibitors; Polyethylene Glycols; Purinergic P2X Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P2X7; Sciatic Neuropathy; Wallerian Degeneration; Wound Healing	2013

Article

Year

Blocking the P2X7 receptor improves outcomes after axonal fusion.

The Journal of surgical research, 2013, Volume: 184, Issue:1

Topics: Action Potentials; Adenosine Triphosphate; Animals; Axons; Benzenesulfonates; Coloring Agents; Drug Carriers; Male; Motor Activity; Nerve Regeneration; Neurosurgical Procedures; Platelet Aggregation Inhibitors; Polyethylene Glycols; Purinergic P2X Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P2X7; Sciatic Neuropathy; Wallerian Degeneration; Wound Healing

2013